Skip to main content

HALOZYME THERAPEUTICS, INC.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

HALO$103.63-15.7%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-32335

(Exact name of registrant as specified in its charter)

Delaware88-0488686
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
12390 El Camino Real92130
San Diego(Zip Code)
California
(Address of principal executive offices)

(858)794-8889

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueHALOThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ Nox

The number of outstanding shares (in thousands) of the registrant’s common stock, par value $0.001 per share, was 114,010 as of October 31, 2026.

TABLE OF CONTENTS

Page
PART I — FINANCIAL INFORMATION
Item 1. · Financial Statements
Condensed Consolidated Balance Sheets (Unaudited) - September 30, 2026 and December 31, 20253
Condensed Consolidated Statements of Income (Unaudited) - Three and Nine Months Ended September 30, 2026 and 20254
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three and Nine Months Ended September 30, 2026 and 20255
Condensed Consolidated Statements of Cash Flows (Unaudited) - Nine Months Ended September 30, 2026 and 20256
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - Three and Nine Months Ended September 30, 2026 and 20258
Notes to Condensed Consolidated Financial Statements (Unaudited)9
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations45
Item 3.Quantitative and Qualitative Disclosures About Market Risk70
Item 4.Controls and Procedures70
PART II — OTHER INFORMATION
Item 1.Legal Proceedings71
Item 1A.Risk Factors71
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds72
Item 3.Defaults Upon Senior Securities74
Item 4.Mine Safety Disclosures74
Item 5.Other Information74
Item 6.Exhibits75
SIGNATURES76
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.